Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 6/20 | 0.47 |
| ▸ | NOS1 | P29475 | 5/20 | 0.47 |
| ▸ | NOS3 | P29474 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ARG2 | P78540 | 4/20 | 0.44 |
| ▸ | ARG1 | P05089 | 3/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12633803 | 0.89 | NOS2 (0.46) | GSRNOS2NOS1NOS3CYP1A2 | |
| SCHEMBL18472741 | 0.86 | NOS2 (0.45) | GSRNOS2NOS1NOS3CYP1A2 | |
| SCHEMBL826663 | 0.84 | GSR (0.50) | GSRNOS2NOS1NOS3CYP1A2 | |
| SCHEMBL25660592 | 0.84 | GSR (0.53) | GSRNOS2NOS1NOS3CYP1A2 | |
| SCHEMBL25662315 | 0.80 | GSR (0.57) | GSRNOS2NOS1NOS3CYP1A2 | |
| SCHEMBL10187385 | 0.79 | TSHR (0.51) | GSRNOS2NOS1NOS3CYP1A2 | |
| SCHEMBL12520127 | 0.79 | NOS2 (0.47) | GSRNOS2NOS1NOS3CYP1A2 | |
| SCHEMBL17072275 | 0.78 | GSR (0.55) | GSRNOS2NOS1NOS3CYP1A2 | |
| SCHEMBL15305190 | 0.78 | NOS2 (0.50) | GSRNOS2NOS1NOS3CYP1A2 | |
| SCHEMBL18493979 | 0.77 | GSR (0.50) | GSRNOS2NOS1NOS3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9962450-B2 | Method of treating heart failure with modified relaxin polypeptides | AMBRX, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9637441-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9452222-B2 | Nucleic acids encoding modified relaxin polypeptides | AMBRX, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150299288-A1 | Modified Insulin Polypeptides and Their Uses | AMBRX, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-9079971-B2 | Modified FGF-21 polypeptides comprising non-naturally occurring amino acids | AMBRX, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150094457-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20140296487-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | AMBRX, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140194357-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130150564-A1 | Modified FGF-21 Polypeptides and Their Uses | AMBRX, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8367612-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120283172-A1 | MODIFIED PORCINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20110178029-A1 | Modified Human Apolipoprotein A-1 and Their Uses | AMBRX, INC. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178029-A1 | Modified Human Apolipoprotein A-1 and Their Uses | APOB, APOL1, HDLBP | GSR 4050/4885NOS2 4258/4885NOS1 3493/4885 |
| US-20150299288-A1 | Modified Insulin Polypeptides and Their Uses | IAPP, INSR, IGFBP4 | GSR 2755/4885NOS2 4146/4885NOS1 4563/4885 |
| US-20140296487-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | FGB, FCGR3B, FCGR2A | GSR 3439/4885NOS2 3197/4885NOS1 3630/4885 |
| US-20150094457-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | GSR 2147/4885NOS2 21/4885NOS1 40/4885 |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP4 | GSR 2028/4885NOS2 1488/4885NOS1 2469/4885 |
| US-20120283172-A1 | MODIFIED PORCINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES | CRH, IAPP, NPPA | GSR 3979/4885NOS2 2637/4885NOS1 3274/4885 |
| US-20140194357-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP4 | GSR 2028/4885NOS2 1488/4885NOS1 2469/4885 |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | KLK3, PTMS, DDOST | GSR 3119/4885NOS2 2024/4885NOS1 1729/4885 |
| US-20130150564-A1 | Modified FGF-21 Polypeptides and Their Uses | FGF2, FGF1, FGF23 | GSR 4651/4885NOS2 2852/4885NOS1 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.